To critically examine the human safety assessments of fluopyram, a succinate dehydrogenase inhibitor, and evaluate the completeness of these assessments in relation to potential toxicities, emphasizing the critical nature of this evaluation.
Key Findings:
Fluopyram underwent nearly 3000 safety studies addressing human and environmental safety.
The studies are designed to identify health hazards and determine tolerable dose levels without adverse effects, conducted under Good Laboratory Practice (GLP) to ensure reliability and trustworthiness.
Interpretation:
The findings suggest that while fluopyram has undergone extensive safety evaluations, concerns remain regarding the potential for missed toxicities related to SDH inhibition, which could have significant health implications.
Limitations:
The studies primarily involve animal testing, which may not fully predict human responses.
Limited published literature on the mammalian toxicity of fluopyram may restrict comprehensive risk assessment, potentially introducing bias.
Conclusion:
The paper emphasizes the complexity and thoroughness of fluopyram's safety studies while acknowledging ongoing concerns about the potential health impacts of SDH inhibitors, underscoring the need for further investigation.
Harold Burstein, MD, PhD, and Jennifer A. Ligibel, MD discuss new research from the Breast Cancer Weight Loss (BWEL) trial, as well as recommendations for lifestyle, diet and GLP1 agonists.
